Crescent Biopharma (CBIO) Financial Statements & Analysis

Crescent Biopharma Income Statement Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Crescent Biopharma, Inc. income statement - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017
Revenue & Gross Profit
Revenue	10.84	0.00	0.01	0.08	1.16	10.16	0.00	0.00	0.00
Cost of Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.90	0.28	0.26
Gross Profit	10.84	0.00	0.01	0.08	1.16	10.16	-0.90	-0.28	-0.26
Operating Expenses
Research & Development	138.09	56.14	20.07	28.39	47.49	44.93	47.03	40.09	24.10
Selling, General & Administrative	25.39	12.63	19.21	19.09	17.12	16.74	14.36	11.41	9.83
Operating Expenses	163.48	40.04	39.29	47.48	64.61	61.67	61.39	51.51	33.67
Operating Income	-152.63	-40.04	-39.28	-47.40	-63.45	-51.51	-61.39	-51.51	-33.93
Other Income/Expense
Interest Income	2.88	0.94	2.38	0.71	0.02	0.48	3.50	3.23	0.65
Interest Expense	2.19	-3.41	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other Income/Expense	0.69	4.32	4.75	0.71	0.02	0.48	3.50	3.23	0.65
Income
Income Before Tax	-151.94	-71.47	-34.52	-46.69	-63.43	-51.03	-57.89	-48.27	-33.28
Income Tax Expense	2.00	0.00	0.00	0.00	0.00	0.00	-3.78	3.23	0.00
Net Income	-153.94	-37.88	-36.90	-46.69	-63.43	-51.03	-54.12	-48.27	-33.28
Net Income - Continuous Operations	-153.94	-48.52	-36.90	-46.69	-63.43	-51.03	-54.12	-48.27	-33.28
Net Income - Discontinued Operations	-	-	-	-	-	-	-	-	-
EBITDA	-152.55	-40.04	-39.12	-47.20	-63.18	-51.24	-56.99	-51.23	-33.67
EBIT	-152.63	-68.76	-39.28	-47.40	-63.45	-	-	-	-
Depreciation & Amortization	0.08	0.04	0.15	0.21	0.26	0.27	0.90	0.28	0.26
Earnings Per Share
Basic EPS	-13.00	-93.00	-58.00	-89.00	-123.00	-112.00	-134.00	-118.00	-113.00
Diluted EPS	-13.00	-59.00	-58.00	-89.00	-123.00	-112.00	-134.00	-118.00	-113.00
Basic Shares Outstanding	12.01	0.77	0.63	0.53	0.51	0.46	0.43	0.41	0.29
Diluted Shares Outstanding	12.01	0.77	0.63	0.53	0.51	0.46	0.43	0.41	0.29

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Crescent Biopharma Financial Statements

What was Crescent Biopharma's revenue in fiscal 2025?

Crescent Biopharma reported revenue of $10.84M in fiscal 2025 (fiscal year ended Dec 31, 2025).

Is Crescent Biopharma profitable?

No. Crescent Biopharma reported a net loss of $153.94M in fiscal 2025. In fiscal 2024 it lost $37.88M.

What is Crescent Biopharma's operating margin?

Crescent Biopharma's operating income was −$152.63M on revenue of $10.84M in fiscal 2025, an operating margin of -1407.5%.

What is net profit margin?

Net profit margin is net income divided by revenue. It shows how much of each dollar of sales a company keeps as profit after all costs, interest and taxes. Full definition